TABLE 3.
Comparison of patients who were vaccinated during follow up (n = 445) vs. those who remained non-vaccinated (n = 666).
| Variable | Pneumococcal vaccine (−) | Pneumococcal vaccine (+) | P-value |
| n = 666 | n = 445 | ||
| Female, n (%) | 536 (81.1%) | 349 (78.6%) | 0.31 |
| Age, years, mean (SD) | 59 (13.9) | 62.6 (11.6) | <0.001 |
| Disease duration, years, mean (SD) | 8.2 (8.2) | 9 (8.8) | 0.15 |
| Early disease (<2 years) | 153 (23%) | 96 (21.6%) | 0.58 |
| RF and/or anti-CCP+, n (%) | 300 (46.9%) | 218 (53.3%) | 0.04 |
| Erosions, n (%) | 174 (37.9%) | 132 (38.6%) | 0.84 |
| Working, n (%) | 241 (38.3%) | 102 (29.2%) | 0.005 |
| Tertiary education, n (%) | 123 (22%) | 50 (16.2%) | 0.04 |
| DAS28-ESR, mean (SD) | 3.25 (1.35) | 3.75 (1.33) | <0.001 |
| HAQ, median (IQR) | 0.13 (0.80) | 0.38 (0.75) | 0.03 |
| Arthroplasties, n (%) | 68 (10.2%) | 37 (8.3%) | 0.29 |
| csDMARDs, n (%) | 553 (83%) | 382 (85.8%) | 0.21 |
| bDMARDs, n (%) | 219 (32.9%) | 193 (43.4%) | <0.001 |
| Glucocorticoids, n (%) | 217 (32.6%) | 157 (35.3%) | 0.35 |
| Glucocorticoids, mg/day, mean (SD) | 5.0 (2.29) | 5.5 (3.2) | 0.12 |
| Current smokers, n (%) | 109 (17.7%) | 79 (18.8%) | 0.65 |
| Alcohol use (>1 day/week) | 37 (5.9%) | 25 (6%) | 0.99 |
| Dyslipidemia, n (%) | 190 (28.5%) | 151 (33.9%) | 0.056 |
| Coronary artery disease, n (%) | 24 (3.6%) | 22 (4.9%) | 0.27 |
| Stroke, n (%) | 15 (2.3%) | 16 (3.6%) | 0.18 |
| Hypertension, n (%) | 256 (38.4%) | 188 (42.2%) | 0.20 |
| Diabetes, n (%) | 82 (12.3%) | 65 (14.6%) | 0.27 |
| COPD and/or RA-ILD, n (%) | 25 (3.8%) | 37 (8.3%) | 0.001 |
| Depression, n (%) | 68 (10.2%) | 54 (12.1%) | 0.31 |
| Osteoporosis, n (%) | 149 (22.4%) | 118 (26.5%) | 0.11 |
| Cancer (current/past), n (%) | 36 (5.4%) | 36 (8.1%) | 0.07 |
| History of hospitalization (last 12 months), n (%) | 47 (7.1%) | 31 (7%) | 0.95 |
| History of serious infection, n (%) | 40 (6%) | 29 (6.5%) | 0.73 |
| BMI, kg/m2, mean (SD) | 27.1 (5.0) | 27.5 (5.3) | 0.21 |
| BMI > 30 kg/m2, n (%) | 142 (21.3%) | 79 (17.8%) | 0.14 |
| RDCI, median (IQR) | 0 (1) | 0 (1) | 0.03 |
| Influenza vaccination during follow-up (at least 1 dose), n (%) | 280 (42%) | 431 (96.9%) | <0.001 |